[Gestonorone therapy of prostatic adenoma].
Clinical trials with gestonorone led to favourable results in 65% of the patients. The drug is recommended particularly to patients in stage I or II of prostatic adenoma. It is justified to prescribe this treatment to high risk patients who cannot be operated because of their serious conditions. An objective assessment of the effect of the drug was possible by means of urodynamic and ultrasound tests which detected also fewer latent changes suggesting a continuation or repetition of the treatment.
D000368:Aged; D002986:Clinical Trials as Topic; D005866:Gestonorone Caproate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014465:Ultrasonics; D014555:Urination Disorders / Q000188:drug therapy / Q000209:etiology; D014563:Urodynamics
D005866:Gestonorone Caproate
Uber die Behandlung des Prostaataadenoms mit Gestenoron.